Precigen, Inc. (PGEN)

NASDAQ: PGEN · Real-Time Price · USD
3.870
-0.020 (-0.51%)
Sep 17, 2025, 3:14 PM EDT - Market open
-0.51%
Market Cap1.15B
Revenue (ttm)4.34M
Net Income (ttm)-124.50M
Shares Out 297.97M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,426,760
Open3.880
Previous Close3.890
Day's Range3.811 - 4.010
52-Week Range0.651 - 5.225
Beta1.82
AnalystsBuy
Price Target7.50 (+93.8%)
Earnings DateNov 13, 2025

About PGEN

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 143
Stock Exchange NASDAQ
Ticker Symbol PGEN
Full Company Profile

Financial Performance

In 2024, Precigen's revenue was $3.93 million, a decrease of -36.95% compared to the previous year's $6.23 million. Losses were -$126.24 million, 31.6% more than in 2023.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 93.80% from the latest price.

Price Target
$7.5
(93.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Precigen Announces Up to $125 Million Non-Dilutive Financing

$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and o...

14 days ago - PRNewsWire

Precigen, Inc. - Special Call

Precigen, Inc. - Special Call Company Participants Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwr...

15 days ago - Seeking Alpha

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of pat...

23 days ago - PRNewsWire

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement...

Other symbols: BMNROKE
26 days ago - Seeking Alpha

Precigen: This Billion-Dollar Approval Is Still Undervalued

PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, t...

4 weeks ago - Seeking Alpha

Why Is Precigen Stock Surging On Friday?

On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).

4 weeks ago - Benzinga

US FDA approves Precigen's immunotherapy for rare respiratory disease

The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regul...

4 weeks ago - Reuters

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FD...

4 weeks ago - PRNewsWire

Precigen: August Is Pivotal For This Biotech Innovator

Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Rec...

2 months ago - Seeking Alpha

Precigen Reports First Quarter 2025 Financial Results and Business Updates

PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA targe...

4 months ago - PRNewsWire

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

– International event will raise awareness and bring together RRP patients , caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilitating, ...

5 months ago - PRNewsWire

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CC...

6 months ago - Seeking Alpha

Precigen Reports Full Year 2024 Financial Results and Business Updates

FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 Results from pivot...

6 months ago - PRNewsWire

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

GERMANTOWN, Md. , March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...

6 months ago - PRNewsWire

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge be...

7 months ago - Seeking Alpha

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious...

7 months ago - PRNewsWire

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

–   PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease  – –   Company completed BLA submission for PRGN-2012 for treatment of adu...

8 months ago - PRNewsWire

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md. , Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...

8 months ago - PRNewsWire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

–   PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated...

9 months ago - PRNewsWire

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

GERMANTOWN, Md. , Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

9 months ago - PRNewsWire

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

–   Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012 †  in RRP under accelerated ap...

10 months ago - PRNewsWire

Precigen to Participate in the Stifel 2024 Healthcare Conference

GERMANTOWN, Md. , Nov. 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

11 months ago - PRNewsWire

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...

1 year ago - PRNewsWire

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.

Other symbols: GGRTITN
1 year ago - Benzinga

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Precigen, Inc. (NASDAQ:PGEN) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Harry Thomasian - CFO Phil Tenn...

1 year ago - Seeking Alpha